<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00473200</url>
  </required_header>
  <id_info>
    <org_study_id>005-210</org_study_id>
    <nct_id>NCT00473200</nct_id>
  </id_info>
  <brief_title>Effect of S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine</brief_title>
  <official_title>Effect of Oral S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine in Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether S-adenosylmethionine (SAMe), a natural
      substance available as a nutritional supplement, can influence blood levels of homocysteine
      (Hcy). More specifically, we will determine if chronic oral SAMe administration affects
      homocysteine metabolism in patients with vascular disease who have mild to moderate
      hyperhomocysteinemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate whether S-adenosylmethionine (SAMe), a natural
      substance available as a nutritional supplement, can influence blood levels of homocysteine
      (Hcy). More specifically, we will determine if chronic oral SAMe administration effects
      homocysteine metabolism in patients with vascular disease who have mild to moderate
      hyperhomocysteinemia through the following specific aims:

      Specific Aim 1 - To determine the effect of oral SAMe (1200 mg/day) on plasma total
      homocysteine levels in subjects with mild to moderate hyperhomocysteinemia.

      Specific Aim 2 - To determine the effect of oral SAMe (1200 mg/day) with and without
      supplementation of folate, vitamin B12 and B6, on plasma homocysteine levels in patients with
      mild to moderate hyperhomocysteinemia.

      Specific Aim 3 - To determine the effect of oral SAMe (1200 mg/day) on plasma levels pf
      asymmetric dimethylarginine (ADMA) in subjects with mild to moderate hyperhomocysteinemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effect of oral SAMe (1200 mg/day) on plasma total homocysteine (tHcy) and asymmetric dimethylagrinine (ADMA) levels in subjects with mild to moderate hyperhomocysteinemia.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effect of oral SAMe (1200 mg/day) with and without supplementation of folate, vitamin B12 and B6, on plasma homocysteine levels in patients with mild to moderate hyperhomocysteinemia.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Hyperhomocysteinemia</condition>
  <arm_group>
    <arm_group_label>S-adenosylmethionine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>S-adenosylmethionine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>S-adenosylmethionine</intervention_name>
    <description>1200 mg daily</description>
    <arm_group_label>S-adenosylmethionine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and older

          -  Must have a serum homocysteine value greater than or equal to 14 Î¼mol/L

          -  Stable weight 3 months prior to study participation

        Exclusion Criteria:

          -  Subjects with a BMI greater than 35 or less than 18

          -  Currently taking B 100 or other high-dose B vitamin supplements within the past 12
             months

          -  Taken methionine or SAMe supplements within the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teodoro Bottiglieri, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Baylor Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2007</study_first_submitted>
  <study_first_submitted_qc>May 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2007</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperhomocysteinemia</keyword>
  <keyword>homocysteine</keyword>
  <keyword>S-adenosylmethionine</keyword>
  <keyword>SAMe</keyword>
  <keyword>Asymmetric dimethylagrinine (ADMA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhomocysteinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

